Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Bhatt, Deepak L., Szarek, Michael, Steg, P. Gabriel, Cannon, Christopher P., Leiter, Lawrence A., McGuire, Darren K., Lewis, Julia B., Riddle, Matthew C., Voors, Adriaan A., Metra, Marco, Lund, Lars H., Komajda, Michel, Testani, Jeffrey M., Wilcox, Christopher S., Ponikowski, Piotr, Lopes, Renato D., Verma, Subodh, Lapuerta, Pablo, Pitt, Bertram·2021·New England Journal of Medicine
DOI 10.1056/nejmoa2030183

Cited by (1,000)

Items 201–300 of 1,000

  1. Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction ( DAPA‐VO 2 ): a randomized clinical trial
    Patricia Palau, Martina Amiguet, Eloy Domínguez, Clara Sastre, Anna Mollar, Julia Seller, José Manuel García Pinilla, Ainoha Larumbe, Alfonso Valle, Juan José Gómez‐Doblas et al. · 2022 · European Journal of Heart Failure
  2. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults
    G.B. John Mancini, Eileen O’Meara, Shelley R. Zieroth, Mathieu Bernier, ALICE Y.Y. CHENG, David Z.I. Cherney, Kim Alexander Connelly, Justin Adrian Ezekowitz, Ronald Goldenberg, Lawrence A. Leiter et al. · 2022 · Canadian Journal of Cardiology
  3. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
    Ruining Zhang, Qingxing Xie, Xi Lu, Rongping Fan, Nanwei Tong · 2024 · Diabetology & Metabolic Syndrome
  4. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty ( EMPRISE ) study
    Elisabetta Patorno, Ajinkya M Pawar, Deborah J. Wexler, Robert J. Glynn, Lily Gui Bessette, Julie M. Paik, Mehdi Najafzadeh, Kimberly Goodnow Brodovicz, Anouk Déruaz‐Luyet, Sebastian Schneeweiß · 2021 · Diabetes Obesity and Metabolism
  5. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events
    Bertram Pitt, Deepak L. Bhatt, Michael J. Szarek, Christopher Paul Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia Breyer Lewis, Matthew C. Riddle, Adriaan A. Voors, Marco Metra et al. · 2023 · JACC Heart Failure
  6. Inflammation in acute heart failure
    Manuel Garofalo, Rossana Corso, Daniela Tomasoni, Marianna Adamo, Carlo Lombardi, Riccardo Maria Inciardi, Cristina Gussago, Carlo Di Mario, Marco Metra, Matteo Pagnesi · 2023 · Frontiers in Cardiovascular Medicine
  7. The Use of Left Ventricular Ejection Fraction in the Diagnosis and Management of Heart Failure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)
    Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayés‐Genís, Ovidiu Dragomir Chioncel, James Chen-Tson Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata et al. · 2025 · European Journal of Heart Failure
  8. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials
    Pedro E P Carvalho, Thiago M. A. Veiga, Ana Cristina Simões e Silva, Douglas Mesadri Gewehr, Caroline Serafim Dagostin, Amanda Dantas Ferreira Fernandes, Guilherme Marmontel Nasi, Rhanderson N. Cardoso · 2023 · Clinical Research in Cardiology
  9. Implementing Guideline-Directed Medical Therapy for Heart Failure
    Harsh H. Patolia, Muhammad Shahzeb Khan, Gregg C. Fonarow, Javed Butler, Stephen John Greene · 2023 · Journal of the American College of Cardiology
  10. Finerenone in Patients With a Recent Worsening Heart Failure Event
    Akshay Suvas Desai, Muthiah Vaduganathan, Brian Lee Claggett, Ian J. Kulac, Pardeep S. Jhund, Jonathan W. Cunningham, Maria Borentain, James Lay‐Flurrie, Prabhakar Viswanathan, Katja Rohwedder et al. · 2024 · Journal of the American College of Cardiology
  11. Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
    Yong‐ho Lee, Soo Kyung Lim, Melanie Jane Davies · 2025 · Nature Reviews Endocrinology
  12. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care
    Samuel Seidu, Xavier Cos, Stephen Brunton, Stewart B. Harris, Stefan P. O. Jansson, Manel Mata‐Cases, A.M.J. Neijens, Pınar Topsever, Kamlesh Khunti · 2022 · Primary care diabetes
  13. Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis
    Hongda Zhang, Lei Ding, Lijie Mi, Ai-Kai Zhang, Kuo Zhang, Zihan Jiang, Fengyuan Yu, Xin-Xin Yan, Yu-Jing Shen, Min Tang · 2023 · European Journal of Preventive Cardiology
  14. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
    Jung‐Im Shin, Yunwen Xu, Alex R. Chang, Juan Jesús Carrero, Carina M. Flaherty, Amrita Mukhopadhyay, Lesley A. Inker, Saul Blecker, Leora Idit Horwitz, Morgan Erika Grams · 2024 · Journal of the American College of Cardiology
  15. A Natural Language Processing–Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System
    Andrew P. Ambrosy, Rishi Parikh, Sue Hee Sung, Anand Narayanan, Rajeev Masson, Phuong-Quang Lam, Kevin Kheder, Alan Iwahashi, Alexander B. Hardwick, Jesse K. Fitzpatrick et al. · 2021 · JAMA Network Open
  16. Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches
    Jing Xu, Taro Hirai, Daisuke Koya, Munehiro Kitada · 2021 · Journal of Clinical Medicine
  17. Integrating Coronary Atherosclerosis Burden and Progression with Coronary Artery Disease Risk Factors to Guide Therapeutic Decision Making
    Andrew M. Freeman, Subha V. Raman, Monica Aggarwal, David Joel Maron, Deepak L. Bhatt, Purvi J. Parwani, John Osborne, James P. Earls, James K. Min, Jeroen Joost Bax et al. · 2022 · The American Journal of Medicine
  18. SGLT1: A Potential Drug Target for Cardiovascular Disease
    Mengnan Zhao, Na Li, Hong Zhou · 2023 · Drug Design Development and Therapy
  19. Clinical Management and Therapeutic Optimization of Patients with Heart Failure with Reduced Ejection Fraction and Low Blood Pressure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC
    Hadi N. Skouri, Nicolas Girerd, Luca Monzo, Mark Colquhoun Petrie, Michael Böhm, Marianna Adamo, Wilfried Müllens, Gianluigi Savarese, Mehmet Birhan Yılmaz, Offer Amir et al. · 2025 · European Journal of Heart Failure
  20. SGLT2 Inhibitors and Their Antiarrhythmic Properties
    Ewald Kolesnik, Daniel Scherr, Ursula Rohrer, Martin Benedikt, Martin Manninger, Harald Sourij, Dirk von Lewinski · 2022 · International Journal of Molecular Sciences
  21. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update
    Salah, Husam M., Al'Aref, Subhi J., Khan, Muhammad Shahzeb, Al-Hawwas, Malek, Vallurupalli, Srikanth, Mehta, Jawahar L., Mounsey, J Paul, Greene, Stephen J., McGuire, Darren K., Lopes, Renato D. et al. · 2021 · American Heart Journal
  22. A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction
    Robert J.H. Miller, Jonathan G. Howlett, Nowell Mark Fine · 2021 · Canadian Journal of Cardiology
  23. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
    Kieran F. Docherty, Modele O. Ogunniyi, Inder S. Anand, Akshay Suvas Desai, Mirta Díez, Jonathan G. Howlett, José Carlos Nicolau, Eileen O’Meara, Subodh Verma, Silvio E. Inzucchi et al. · 2021 · JACC Heart Failure
  24. Recurrent Events in Cardiovascular Trials
    John Gregson, Gregg W. Stone, Deepak L. Bhatt, Milton Packer, Stefan D. Anker, Cordula Zeller, Björn Redfors, Stuart Pocock · 2023 · Journal of the American College of Cardiology
  25. Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
    David Z.I. Cherney, Jacob Allen Udell, Daniel J. Drucker · 2021 · Med
  26. Epicardial Fat Expansion in Diabetic and Obese Patients with Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype
    Elsanhoury, Ahmed, Nelki, Vivian, Kelle, Sebastian, Van Linthout, Sophie, Tschöpe, Carsten · 2021 · Frontiers in Cardiovascular Medicine
  27. Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?
    Scheen, André J., Bonnet, Fabrice · 2023 · Diabetes & Metabolism
  28. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study
    Kristina V. Charaya, Dmitry Shchekochikhin, Denis A. Andreev, Irina Dyachuk, Svetlana Tarasenko, Maria G. Poltavskaya, Меситская Динара Фератовна, Alexandra A. Bogdanova, Natalia Ananicheva, А. A. Kuzub · 2022 · Open Heart
  29. SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
    Roko Škrabić, Marko Kumrić, Josip Vrdoljak, Doris Rušić, Ivna Skrabic, Marino Vilović, Dinko Martinović, Vid Duplancic, Tina Tičinović Kurir, Joško Božić · 2022 · Biomedicines
  30. Cardio-renal benefits of sodium–glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence
    Jose S. Aguilar-Gallardo, Ashish Adrian Correa, Johanna Contreras · 2021 · European Heart Journal - Cardiovascular Pharmacotherapy
  31. Effects of an outpatient intervention comprising nurse‐led non‐invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure ( AMULET study): a randomised controlled trial
    Paweł Krzesiński, Ewa Anita Jankowska, Janusz Siebert, Agata Anna Galas, Katarzyna Piotrowicz, Adam Stańczyk, Paweł Siwołowski, Piotr G. Gutknecht, Paweł Chrom, Piotr Murawski et al. · 2021 · European Journal of Heart Failure
  32. The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction
    Nicholas Keisuke Brownell, Boback Ziaeian, Gregg C. Fonarow · 2021 · Cardiac failure review
  33. Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
    Husam M. Salah, Subodh Verma, Carlos G. Santos‐Gallego, Ankeet S. Bhatt, Muthiah Vaduganathan, Muhammad Shahzeb Khan, Renato D. Lópes, Subhi Jamal Alaref, Darren K. McGuire, Marat Fudim · 2022 · Journal of Cardiovascular Translational Research
  34. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease
    David Z.I. Cherney, Ele Ferrannini, Guillermo E. Umpierrez, Anne L. Peters, Julio Rosenstock, David R. Powell, Michael J. Davies, Phillip Lee Banks, Rajiv Agarwal · 2023 · Diabetes Obesity and Metabolism
  35. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry
    Stephen John Greene, Justin Adrian Ezekowitz, Kevin Joseph Anstrom, Vladimir Demyanenko, Michael M. Givertz, Ileana L. Piña, Christopher M. O’Connor, Joerg Koglin, Lothar Roessig, Adrian F. Hernandez et al. · 2022 · Journal of Cardiac Failure
  36. Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain
    Carlos Escobar, Beatriz Palacios, Luis F. Varela, Martín Gutiérrez, Mai Duong, Hungta Chen, Nahila Justo, Javier Cid-Ruzafa, Ignacio Hernández, Phillip R. Hunt et al. · 2022 · Journal of Clinical Medicine
  37. A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma
    Royce W. Zhou, Jia Xu, Tiphaine C. Martin, Alexis L. Zachem, Cijiang He, Sait Ozturk, Deniz Demircioğlu, Ankita Bansal, Andrew Paul Trotta, Bruno Giotti et al. · 2022 · Nature Communications
  38. Mineralocorticoid receptor antagonists with sodium–glucose co-transporter-2 inhibitors in heart failure: a meta-analysis
    Mainak Banerjee, Indira Maisnam, Rimesh Pal, Satinath Mukhopadhyay · 2023 · European Heart Journal
  39. Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes
    Peter Hanlon, Elaine W. Butterly, Lili S. Wei, Heather Wightman, Saleh Ali Almazam, Khalid Alsallumi, Jamie Crowther, Ryan McChrystal, Heidi Rennison, Katherine Hughes et al. · 2025 · JAMA
  40. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
    Takeshi Kitai, Shun Kohsaka, Takao Kato, Eri Toda Kato, Kimi Sato, KANAKO TERAMOTO, Hidenori Yaku, Eiichi Akiyama, Masahiko Ando, Chisato Izumi et al. · 2025 · Journal of Cardiac Failure
  41. Epicardial adipose tissue in obesity-related cardiac dysfunction
    Sarah L Ayton, Gaurav Singh Gulsin, Gerry Patrick McCann, Alastair James Moss · 2021 · Heart
  42. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options
    Jean‐Sébastien Hulot, Jean‐Noël Trochu, Erwan Donal, Michel Galinier, Damien Logeart, Pascal de Groote, Yves Juillière · 2021 · Expert Opinion on Pharmacotherapy
  43. Drug Layering in Heart Failure
    Giuseppe M.C. Rosano, Larry A. Allen, Amr Abdin, JoAnn M. Lindenfeld, Eileen O’Meara, Carolyn S.P. Lam, Patrizio Lancellotti, Gianluigi Savarese, Stephen S. Gottlieb, John R. Teerlink et al. · 2021 · JACC Heart Failure
  44. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
    Bertram Pitt, Philippe Gabríel Steg, Lawrence A. Leiter, Deepak L. Bhatt · 2021 · Cardiovascular Drugs and Therapy
  45. Heart failure in adults with congenital heart disease
    Margarita Brida, Daniel Lovrić, Massimo Griselli, Fernando Gil, Michael Α. Gatzoulis · 2022 · International Journal of Cardiology
  46. Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
    Giugliano, Dario, Longo, Miriam, Scappaticcio, Lorenzo, Caruso, Paola, Esposito, Katherine · 2021 · Cardiovascular Diabetology
  47. Effects of da pagliflozin on prevention of major clinical events and recovery in patients with re spiratory failure because of COVID‐ 19 : Design and rationale for the DARE‐19 study
    Mikhail Kosiborod, Otavio B Berwanger, Gary G. Koch, Felipe A. Martínez, Omar Mukhtar, Subodh Verma, Vijay Chopra, Ali Javaheri, Phil Ambery, Samvel B. Gasparyan et al. · 2020 · Diabetes Obesity and Metabolism
  48. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 ( SGLT2 ) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database
    Ameenathul M. Fawzy, José Miguel Rivera‐Caravaca, Paula Underhill, Laurent Fauchier, Gregory Y.H. Lip · 2022 · Diabetes Obesity and Metabolism
  49. New Insights into the Use of Empagliflozin—A Comprehensive Review
    Joanna Forycka, Joanna Hajdys, Julia Krzemińska, Piotr Wilczopolski, Magdalena Wronka, Ewelina Młynarska, Jacek Rysz, Beata Franczyk · 2022 · Biomedicines
  50. SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
    Marco Valerio Mariani, Giovanna Manzi, Nicola Pierucci, Domenico Laviola, Agostino Piro, Andrea D’Amato, Domenico Filomena, Andrea Matteucci, Paolo Severino, Fabio Miraldi et al. · 2024 · Journal of Cardiovascular Electrophysiology
  51. Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
    Antoni Bayés‐Genís, Oriol Iborra Egea, Giosafat Spitaleri, Mar Domingo, Elena Revuelta‐López, Pau Codina, Germán Cediel, Evelyn Santiago‐Vacas, Adriana Cserkóová, Domingo Andrés Pascual-Figal et al. · 2021 · Scientific Reports
  52. SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
    Manuel Alfredo Podestà, Gianmarco Sabiu, Andrea Galassi, Paola Ciceri, Mario Gennaro Cozzolino · 2023 · Biomedicines
  53. Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis
    Frederick Berro Rivera, Vincent Anthony Songheng Tang, Deogracias Villa De Luna, Edgar V. Lerma, Krishnaswami Vijayaraghavan, Amir Kazory, Nilay S. Shah, Annabelle Santos Volgman · 2023 · American Heart Journal Plus Cardiology Research and Practice
  54. The double burden: type 1 diabetes and heart failure—a comprehensive review
    María Teresa Julián, Alejandra Pérez-Montes de, Josep Julve, Núria Alonso · 2024 · Cardiovascular Diabetology
  55. SGLT2i Versus ARNI in Heart Failure with Reduced Ejection Fraction: A Systematic Review and Meta-Analysis
    Yuling Yan, Bin Liu, Jun Cheng Du, Jing Wang, Xiaodong Jing, Yajie Liu, Songbai Deng, Jianlin Du, Qiang She · 2021 · ESC Heart Failure
  56. Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
    Yi-Wen Yu, Xue-Mei Zhao, Yun-Hong Wang, Qiong Zhou, Yan Huang, Mei Zhai, Jian Zhang · 2021 · Cardiovascular Diabetology
  57. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
    Silvio E. Inzucchi, Brian Lee Claggett, Muthiah Vaduganathan, Akshay Suvas Desai, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez et al. · 2022 · The Lancet Diabetes & Endocrinology
  58. Management of type 2 diabetes in chronic kidney disease
    Jefferson L. Triozzi, L. Parker Gregg, Salim S. Virani, Sankar Dass Navaneethan · 2021 · BMJ Open Diabetes Research & Care
  59. Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
    Peter Moritz Becher, Benedikt Schrage, Giulia Ferrannini, Lina Benson, Javed Butler, Juan Jesús Carrero, Francesco Cosentino, Ulf Dahlström, Linda Mellbin, Giuseppe M.C. Rosano et al. · 2021 · European Journal of Heart Failure
  60. SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
    Daria Adamczak, Natasha Ahmed, Hamza Tariq, Malsha Walgamage, THILINI WALGAMAGE, Azad Mohammed, Jadzia Tin-Tsen Chou, Marta Kałużna‐Oleksy, Maciej Lesiak, Ewa Straburzyńska‐Migaj · 2022 · Journal of Clinical Medicine
  61. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
    Panagiotis Theofilis, Μarios Sagris, Evangelos K. Oikonomou, Alexios S. Antonopoulos, Gerasimos Siasos, Kostas Tsioufis, Dimitris Tousoulis · 2022 · Diabetes Research and Clinical Practice
  62. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis
    Mahmoud Barbarawi, Ahmad Al‐Abdouh, Owais Barbarawi, Harini G. Lakshman, Mariam Al kasasbeh, Kai Chen · 2021 · Heart Failure Reviews
  63. Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure
    Gianmarco Alcidi, Giovanni Goffredo, Michele Correale, Natale Daniele Brunetti, Massimo Iacoviello · 2022 · Journal of Clinical Medicine
  64. Consensus statement on the current pharmacological prevention and management of heart failure
    Andrew Paul Sindone, Carmine G. De Pasquale, John V. Amerena, C. Burdeniuk, Alicia Chan, Andrew J.S. Coats, David L. Hare, Peter Simon Macdonald, Aaron Leonid Sverdlov, John James Atherton · 2022 · The Medical Journal of Australia
  65. Safety, Tolerability and Efficacy of Up-Titration of Guideline-Directed Medical Therapies for Acute Heart Failure in Elderly Patients: A Sub-Analysis of the STRONG-HF Randomized Clinical Trial
    Mattia Arrigo, Jan Biegus, Ayu Asakage, Alexandre Mebazaa, Beth A. Davison, Christopher Edwards, Marianna Adamo, Marianela Barros, Jelena Čelutkienė, Kamilė Čerlinskaitė‐Bajorė et al. · 2023 · European Journal of Heart Failure
  66. Comparison of Effectiveness Among Different Sodium‐Glucose Cotransoporter‐2 Inhibitors According to Underlying Conditions: A Network Meta‐Analysis of Randomized Controlled Trials
    Ryoma Kani, Atsuyuki Watanabe, Yoshihisa Miyamoto, Kentaro Ejiri, Masao Iwagami, Hisato Takagi, Leandro N. Slipczuk, Yusuke Tsugawa, Tadao Aikawa, Toshiki Kuno · 2024 · Journal of the American Heart Association
  67. Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
    Stephan von Haehling, Birgit Aßmus, Tarek Bekfani, Elke Dworatzek, Frank Edelmann, Djawid Hashemi, Kristian Hellenkamp, Tibor Kempf, Philipp Raake, Katharina Andrea Schütt et al. · 2024 · Clinical Research in Cardiology
  68. Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs
    Nikolaos Theodorakis, Maria Nikolaou · 2025 · Biomedicines
  69. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
    Xiaodan Wang, Jingyu Ni, Rui Guo, Lan Li, Jing Su, Feng He, Guanwei Fan · 2021 · Heart Failure Reviews
  70. Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
    Gloria M. Gager, Georg Gelbenegger, Bernd Jilma, Dirk von Lewinski, Harald Sourij, Ceren Eyileten, Krzysztof Jerzy Filipiak, Marek A Postula, Jolanta Maria Siller-Matula · 2021 · Frontiers in Cardiovascular Medicine
  71. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population
    Tonje Thorvaldsen, Giulia Ferrannini, Linda Mellbin, Lina Benson, Francesco Cosentino, John J.V. McMurray, Ulf Dahlström, Lars H. Lund, Gianluigi Savarese · 2022 · Journal of Cardiac Failure
  72. A Year in Heart Failure: An Update of Recent Findings
    Lorenzo Stretti, Dauphine Zippo, Andrew J.S. Coats, Markus S. Anker, Stephan von Haehling, Marco Metra, Daniela Tomasoni · 2021 · ESC Heart Failure
  73. Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression
    José M. Rodriguez‐Valadez, Malak Tahsin, Kirsten E. Fleischmann, Umesh B. Masharani, Joseph Yeboah, Meyeon Park, Lihua Li, Ellerie S. Weber, Yan Li, Asem Berkalieva et al. · 2023 · Diabetes Care
  74. Inflammation as a therapeutic target in heart failure with preserved ejection fraction
    Zhen Hui Peh, Adel Dihoum, Dana Louise Hutton, J. Simon C. Arthur, Graham Rena, Faisel Khan, Chim Choy Lang, Ify R. Mordi · 2023 · Frontiers in Cardiovascular Medicine
  75. Acute heart failure: current pharmacological treatment and perspectives
    Benjamin Deniau, Maria Rosa Costanzo, Karen S Sliwa, Ayu Asakage, Wilfried Müllens, Alexandre Mebazaa · 2023 · European Heart Journal
  76. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
    Jui‐Yi Chen, Heng‐Chih Pan, Chih‐Chung Shiao, Min‐Hsiang Chuang, Chun Yin See, Tzu-Hsuan Yeh, Yafei Yang, Wen-Kai Chu, Vin‐Cent Wu · 2023 · Cardiovascular Diabetology
  77. Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease
    Nisha Bansal, Leila R. Zelnick, Rebecca Scherzer, Michelle M. Estrella, Michael G. Shlipak · 2024 · Circulation Heart Failure
  78. Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies
    Amr Abdin, Michael Böhm, Bahira Shahim, Patric Karlström, Saarraaken Kulenthiran, Hadi N. Skouri, Lars H Lund · 2024 · International Journal of Cardiology
  79. Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
    Yu-Jen Wang, Francesco Paneni, Sokrates Stein, Christian M. Matter · 2021 · Frontiers in Physiology
  80. The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
    Vasiliki Tsampasian, Ranu Baral, Rahul Kumar Chattopadhyay, Maciej Dębski, Shruti Shree Joshi, Johannes Reinhold, Marc Richard Dweck, Pankaj Garg, Vassilios S. Vassiliou · 2021 · Cardiology Research and Practice
  81. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
    Finnian R. Mc Causland, Brian Lee Claggett, Muthiah Vaduganathan, Akshay Suvas Desai, Pardeep S. Jhund, Orly Vardeny, James Chen-Tson Fang, Rudolf A. de Boer, Kieran F. Docherty, Adrian F. Hernandez et al. · 2023 · JAMA Cardiology
  82. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction
    Muthiah Vaduganathan, Jonathan W. Cunningham, Brian Lee Claggett, Finnian Mc Causland, Ebrahim Barkoudah, Peter V. Finn, Faiez M. Zannad, Marc Alan Pfeffer, Adel R. Rizkala, Shalini V. Sabarwal et al. · 2021 · JACC Heart Failure
  83. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms
    Gianluigi Savarese, Javed Butler, Lars H. Lund, Deepak L. Bhatt, Stefan D. Anker · 2021 · Cardiovascular Research
  84. Vericiguat for Heart Failure with Reduced Ejection Fraction
    Carlo Lombardi, Giuliana Cimino, Matteo Pagnesi, Andrea Dell’Aquila, Daniela Tomasoni, Alice Ravera, Riccardo Maria Inciardi, Valentina Carubelli, Enrico Vizzardi, Savina Nodari et al. · 2021 · Current Cardiology Reports
  85. Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines
    Hiroyuki Tsutsui · 2022 · Pharmacology & Therapeutics
  86. Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes?
    Bertram Pitt, Deepak L. Bhatt · 2021 · Circulation
  87. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis
    Jiao Chen, Chunxia Jiang, Man Guo, Yan Zeng, Zongzhe Jiang, Dongmin Zhang, Mengqin Tu, Xiaozhen Tan, Pijun Yan, Xun-Mei Xu et al. · 2024 · Cardiovascular Diabetology
  88. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials
    Lu Yuan, Fei Li, Yong Fan, Yang Yu, Minglong Chen, Jue Xi · 2021 · European Journal of Internal Medicine
  89. Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
    Riccardo Nevola, Maria Alfano, Pia Clara Pafundi, Chiara Brin, Felice Gragnano, Paolo Calabrò, Luigi Elio Adinolfi, Luca Rinaldi, Ferdinando Carlo Sasso, Alfredo Caturano · 2022 · Reviews in Cardiovascular Medicine
  90. SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis
    Razuk, Victor, Chiarito, Mauro, Cao, Davide, Nicolas, Johny, Pivato, Carlo A, Camaj, Anton, Power, David, Beerkens, Frans, Jones, Davis, Alter, Aviv et al. · 2022 · European Heart Journal - Cardiovascular Pharmacotherapy
  91. Side effects and treatment initiation barriers of sodium–glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta‐analysis
    Davor Vukadinović, Amr Abdin, Stefan D. Anker, Giuseppe M.C. Rosano, Felix Mahfoud, Milton Packer, Javed Butler, Michael Böhm · 2022 · European Journal of Heart Failure
  92. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis
    Mainak Banerjee, Rimesh Pal, Kirthana Nair, Satinath Mukhopadhyay · 2023 · Indian Heart Journal
  93. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
    Anjay Rastogi, James L. Januzzi · 2023 · Journal of Clinical Medicine
  94. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure
    Kangyu Chen, Zhiqiang Nie, Rui Shi, Dahai Yu, Qi Wang, Fang Shao, Guohong Wu, Zhenqiang Wu, Tao Chen, Chao Li · 2023 · JAMA Network Open
  95. 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association
    Shinae Kang, Seon Mee Kang, Jong Han Choi, Seung‐Hyun Ko, Bo Kyung Koo, Hyuk-Sang Kwon, Mi Kyung Kim, Sang Yong Kim, Soo‐Kyung Kim, Young‐Eun Kim et al. · 2025 · Diabetes & Metabolism Journal
  96. Acute Heart Failure After Non-Cardiac Surgery: Incidence, Phenotypes, Determinants and Outcomes
    Danielle Menosi Gualandro, Christian Puelacher, Michelle S. Chew, Henrik Andersson, Giovanna Lurati Buse, Noemi Glarner, Daria Mueller, Francisco Akira Malta Cardozo, Katrin Burri‐Winkler, Constantin Mork et al. · 2023 · European Journal of Heart Failure
  97. The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF)
    Abdelrahman N. Emara, Moheb Wadie, Noha O. Mansour, Mohamed E. E. Shams · 2023 · European Journal of Pharmacology
  98. Left ventricular ejection fraction as the primary heart failure phenotyping parameter
    Lars H. Lund, Bertram Pitt, Marco Metra · 2022 · European Journal of Heart Failure
  99. Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
    Zofia Wicik, A Nowak, Joanna Jarosz-Popek, Marta Wolska, Ceren Eyileten, Jolanta Maria Siller-Matula, Dirk von Lewinski, Harald Sourij, Krzysztof Jerzy Filipiak, Marek A Postula · 2022 · Frontiers in Pharmacology
  100. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities
    Mak, Koon-Hou, Vidal-Petiot, Emmanuelle, Young, Robin, Sorbets, Emmanuel, Greenlaw, Nicola, Ford, Ian, Tendera, Michal, Ferrari, Roberto, Tardif, Jean-Claude, Udell, Jacob A et al. · 2022 · European Journal of Preventive Cardiology